MedWaves has received the Taiwan Food and Drug Administration (TFDA) approval for its AveCure microwave coagulation-ablation (MWA) system.
The microwave system consists of a generator, extension cable set, and an array of single-patient-use microwave-probe devices which provide clinicians with patented, fully integrated real-time temperature, both forward and reverse-power feedback to control energy delivery intelligently.
MedWaves MWA system uses microwave energy to volumetrically coagulate-ablate soft-tissue lesions and aids interventional radiologists and surgeons to treat soft-tissue lesions, such as tumors.
The company plans to bring its technology to treat lesions in other locations in the body other than bone, kidney, liver, lung and pancreas.
MedWaves said that it will work with its Taiwanese distributor-partners to schedule and conduct clinical evaluations for the sale of its AveCure system in key hospitals in Taiwan.